ClinicalTrials.gg

Acromegaly clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 202 studies for Acromegaly across more than 10 countries. 19 are recruiting or about to start. 183 of them are mainly about Acromegaly (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-03.

Status

Completed
127
Status unknown
30
Terminated
17
Recruiting
14
Not yet recruiting
5
Withdrawn
5

Phase

Phase 3
34
Phase 2
27
Phase 4
25
Phase 1
12

Where

United States
64
Italy
45
France
37
Germany
34
United Kingdom
31
Poland
27

Who develops what

Add Acromegaly to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 6 programs from 6 companies, 6 with this as their studies’ main aim; 2 with a live phase 3 study; 1 primary completion in the next 12 months. Compare AstraZeneca, CSPC Pharmaceutical Group and Debiopharm here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
OctreotideRecent, limited
Evidence
  • NCT07814651 · CSPC Pharmaceutical Group Limited · Phase 2 · comparator · “Sandostatin LAR” · registered Sep 2026
  • NCT02217800 · Aspireo Pharmaceuticals Limited · Phase 2 · background · “octreotide” · registered Aug 2014
  • NCT02235987 · Aspireo Pharmaceuticals Limited · Phase 2 · background · “octreotide” · registered Aug 2014
  • NCT02111044 · Italfarmaco · Phase 2 · comparator · “Octreotide” · registered Apr 2014
Novartis58% of its industry studiesUS: off-patent, 10 generics marketedEU: Camurus AB (EMA 2025)11 study
pegvisomantEarlier only
Evidence
  • NCT01278342 · Novartis · Phase 4 · background · “pegvisomant” · registered Jan 2011
  • NCT00383708 · Ipsen · Phase 3 · background · “Pegvisomant” · registered Oct 2006
Pfizer80% of its industry studiesEU: Pfizer (EMA 2002)00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
Octreotide Sustained-release Formulation Debio 4126☆ Track1 live phase-3 study: NCT06930625Debiopharm
SYHX2008☆ Track1 live phase-3 study: NCT07623824CSPC Pharmaceutical Group Limited

The 2 in phase 3 with the nearest primary completion, of 6 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Aug 2027 est.MAR002 · Marea Therapeutics · Phase 2 main aimNCT07641179 A Study to Evaluate MAR002 for Acromegaly — primary endpoint: Number of participants with TEAEs (treatment-emergent adverse events), SAEs (serious adverse events), and other laboratory endpoints · 72 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Acromegaly studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

3studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 3

Who these studies take

Of the 14 Acromegaly studies recruiting now, 7 (50%) set no upper age limit and 5 (36%) stop at 75 or younger. 2 (14%) take children under 18. 0 (0%) are for women only and 1 (7%) for men only; 4 (29%) take healthy volunteers.

Recruiting studies that take each age, of 14
AgeWomenMen
102 (14%)2 (14%)
1812 (86%)13 (93%)
3013 (93%)14 (100%)
4013 (93%)14 (100%)
5013 (93%)13 (93%)
6512 (86%)12 (86%)
7511 (79%)11 (79%)
858 (57%)8 (57%)

Across all 202 studies, recruiting or not: 28% stop at 75 or younger and 9% at 65; 5% take children; 1% are for women only and 2% for men only; 16% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Acromegaly studies take

Of 26 observational studies under Acromegaly, half reached primary completion within 85 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Observational85 mo38–263 · 26 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Stopped1

Studies

Recruiting first, then most recently updated. Showing 50 of 202. Browse all 202 → or search them.